Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The acute erythroleukemias.

F M Mazzella1, C Alvares, A Kowal-Vern

  • 1Diarion Systems, Stratford, Connecticut, USA. fmazz65@aol.com

Clinics in Laboratory Medicine
|March 7, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heinz-Lippmann disease: A case of a non-healing wound.

Semergen·2026
Same author

Cecal wedge resection appendectomy for the management of appendiceal polyps.

Techniques in coloproctology·2016
Same author

Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality.

The Journal of hospital infection·2006
Same author

Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6.

Journal of clinical pathology·2002
Same author

Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma.

Bone marrow transplantation·2002
Same author

The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury.

Burns : journal of the International Society for Burn Injuries·2001

Acute erythroleukemia (M6) is an aggressive blood cancer with subtypes M6a, M6b, and M6c. Poor prognosis correlates with specific cellular and genetic factors, necessitating targeted therapies.

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Acute erythroleukemia is an aggressive leukemia originating from multipotential stem cells.
  • It is characterized by distinct subtypes (M6a, M6b, M6c) based on blast and pronormoblast percentages.
  • The disease typically carries a poor prognosis.

Purpose of the Study:

  • To describe the subtypes of acute erythroleukemia.
  • To identify prognostic factors associated with poor outcomes in acute erythroleukemia.
  • To suggest therapeutic strategies for improving patient outcomes.

Main Methods:

  • Classification of acute erythroleukemia into subtypes M6a, M6b, and M6c based on morphological criteria.
  • Correlation analysis of prognostic indicators including pronormoblast:myeloblast ratio, cytogenetic aberrations, proliferative index, and P-glycoprotein expression.

Related Experiment Videos

  • Review of existing therapeutic approaches.

    • Main Results:

    • Subtypes M6a, M6b, and M6c are defined by specific percentages of blasts and pronormoblasts.
    • Poor prognosis is linked to a high pronormoblast:myeloblast ratio, unfavorable cytogenetics, high proliferation, and P-glycoprotein expression.
    • P-glycoprotein expression indicates a multidrug resistance phenotype.

    Conclusions:

    • Understanding the subtypes and prognostic factors is crucial for managing acute erythroleukemia.
    • Targeted chemotherapeutic regimens addressing pronormoblast:myeloblast ratio, cytogenetics, proliferation, and multidrug resistance are needed.
    • Developing specific treatment strategies holds promise for improving outcomes in this aggressive leukemia.